Non-Executive Board Member
Sander Slootweg is Managing Partner at Forbion, Naarden, The Netherlands. He co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion in 2006 and currently serves on the boards of several portfolio companies including Replimune (REPL), NorthSea Therapeutics (Chair), Xention, Oxyrane and New Amsterdam (Chair). Sander also holds responsibility for Forbion’s investment in uniQure (QURE). He was instrumental in several of Forbion’s major exits: Dezima was sold to Amgen for up to USD 1.55 billion, Biovex was acquired by Amgen in 2011 for up to USD 1 billion and Fovea was acquired by Sanofi in 2009 for up to EUR 390 million.
Before co-founding Forbion, Sander was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).
Sander holds a Master degree in Economics and Finance from the Free University of Amsterdam and a Bachelor in Business Administration from Nijenrode University, The Netherlands.